-+ 0.00%
-+ 0.00%
-+ 0.00%

Novartis announced that Pluvicto has been approved by the FDA for PSMA-positive metastatic hormone-sensitive prostate cancer, which is expected to drive new standards for the treatment of metastatic prostate cancer.

Zhitongcaijing·07/31/2026 20:33:25
Listen to the news
Novartis announced that Pluvicto has been approved by the FDA for PSMA-positive metastatic hormone-sensitive prostate cancer, which is expected to drive new standards for the treatment of metastatic prostate cancer.